• Law Debenture's net asset value fell 0.6% in October 2026, trailing the FTSE All-Share benchmark's 1.1% gain.
• Industrial holdings, underweight positions in Shell and AstraZeneca, and exposure to AI-linked energy companies weighed on relative performance.
• Year-to-date NAV total return with debt at fair value reached 14.4%, versus the benchmark's 11.1%.
• The share price stood at 1,172p on October 30, a 2.89% discount to NAV.
• Healthcare positions in Roche and Becton Dickinson were sold, with proceeds partly reinvested in AstraZeneca and GSK.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Law Debenture Corporation plc published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.